与背景人群相比，胃腺癌幸存者的生存期是否更长、更短或相似尚不清楚。这些知识有助于制定基于证据的监测策略、医疗保健建议以及为患者和家庭提供的信息。这项基于人群的队列研究包括 2006 年至 2015 年在瑞典因胃腺癌接受胃切除术且术后存活 ≥ 5 年的所有患者。对他们进行随访直至死亡、术后第 10 年或研究期结束（2020 年 12 月 31 日）。使用生命表方法，将观察到的生存率除以预期生存率，得出具有 95% 置信区间 (CI) 的相对生存率。预期生存率来自相应年龄、性别和日历年的瑞典全体人口。数据来自病历和全国登记。所有 767 名胃腺癌幸存者的生存期均短于预期。每个随访年的相对生存率下降均有所增加，从第 6 年的 97.3% (95% CI 95.4-99.1%) 增加到第 10 年的 86.6% (95% CI 82.3-90.9%)。相对生存率的下降更为明显在早期日历年接受过胃切除术的患者中（2011-2015 年 82.9% [95% CI 77.4-88.4%] 10 年级），受教育时间较短（85.2% [95% CI 77.4-93.0%] 10 年级教育 ≤ 9年），更多合并症（78.0% [95% CI 63.9-92.0%] 第 10 年，Charlson 合并症评分 ≥ 2），并且没有新辅助治疗（83.2% [95% CI 77.4-89.0%] 第 10 年）。胃腺癌幸存者似乎比相应背景人群的生存率更差，特别是在某些亚组中。© 2024。作者。

It is unknown if gastric adenocarcinoma survivors have longer, shorter, or similar survival compared to the background population. This knowledge could contribute to evidence-based monitoring strategies, healthcare recommendations, and information for patients and families.This population-based cohort study included all patients who underwent gastrectomy for gastric adenocarcinoma between 2006-2015 in Sweden and survived ≥ 5 years after surgery. They were followed up until death, postoperative year 10, or end of study period (31 December, 2020). Division of the observed by the expected survival yielded relative survival rates with 95% confidence intervals (CIs) using the life table method. The expected survival was derived from the entire Swedish population of the corresponding age, sex, and calendar year. Data came from medical records and nationwide registers.The survival among all 767 gastric adenocarcinoma survivors was shorter than the expected. The reduction in relative survival increased for each follow-up year, from 97.3% (95% CI 95.4-99.1%) year 6 to 86.6% (95% CI 82.3-90.9%) year 10. The decline in relative survival was more pronounced among patients who had gastrectomy in earlier calendar years (82.9% [95% CI 77.4-88.4%] year 10 for years 2011-2015), shorter education (85.2% [95% CI 77.4-93.0%] year 10 for education ≤ 9 years), more comorbidities (78.0% [95% CI 63.9-92.0%] year 10 for Charlson comorbidity score ≥ 2), and no neoadjuvant therapy (83.2% [95% CI 77.4-89.0%] year 10).Gastric adenocarcinoma survivors seem to have poorer survival than the corresponding background population, particularly in certain subgroups.© 2024. The Author(s).